Keybanc Maintains Overweight on Remitly Global, Raises Price Target to $15

Keybanc analyst Josh Beck maintains Remitly Global (NASDAQ:RELY) with a Overweight and raises the price target from $14 to $15.

byBenzinga Newsdesk

February 23, 2023

1 minute read

Keybanc analyst Josh Beck maintains Remitly Global (NASDAQ:RELY) with a Overweight and raises the price target from $14 to $15.

Hecla Mining Q3 Adj EPS $(0.02), Same YoY, Sales $146.34M Miss $171.57M Estimate

By Benzinga Newsdesk

Today, 11:34 PM

Hecla Mining (NYSE:HL) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year. The company reported quarterly sales of $146.34 million which missed the analyst consensus

Morgan Stanley Maintains Underweight on Wayfair, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 11:34 PM

Morgan Stanley analyst Simeon Gutman maintains Wayfair (NYSE:W) with a Underweight and lowers the price target from $65 to $30.

News

Sio Gene Therapies To Present New Data At The European Society Of Gene And Cell Therapy Virtual Congress 2021

By Benzinga Newsdesk

Today, 11:34 PM

Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new

SIOX

ABM Industries Q4 Adj. EPS $0.85 Beats $0.80 Estimate, Sales $1.70B Beat $1.64B Estimate

By Bill Haddad

Today, 11:34 PM

ABM Industries (NYSE:ABM) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.80 by 6.25 percent. This is a 23.19 percent increase over earnings of $0.69 per share from the same

ABM

Keybanc Maintains Overweight on Remitly Global, Raises Price Target to $15

Related Posts

Hecla Mining Q3 Adj EPS $(0.02), Same YoY, Sales $146.34M Miss $171.57M Estimate

Morgan Stanley Maintains Underweight on Wayfair, Lowers Price Target to $30

Sio Gene Therapies To Present New Data At The European Society Of Gene And Cell Therapy Virtual Congress 2021

ABM Industries Q4 Adj. EPS $0.85 Beats $0.80 Estimate, Sales $1.70B Beat $1.64B Estimate